<DOC>
	<DOCNO>NCT01897987</DOCNO>
	<brief_summary>This follow-up study investigate long-term safety efficacy PNEUMOSTEM® versus placebo , treatment BPD premature infant . Subjects participate complete initial stage Phase II trial ( NCT01297205 ) followed-up 60 month correct age .</brief_summary>
	<brief_title>Follow-up Safety Efficacy Evaluation Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial</brief_title>
	<detailed_description>Subjects complete initial stage Phase II clinical trial followed-up 7 additional visit : correct age 6 , 12,18 , 24 , 36 , 48 , 60 month .</detailed_description>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>Subject complete safety efficacy evaluation Pneumostem Phase II clinical trial Subject write consent form sign legal representative parent upon explanation clinical trial Subject whose parent legal representative agree participate study subject consider inappropriate participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>7 Months</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Human Umbilical Cord Blood Derived Mesenchymal Stem Cells</keyword>
	<keyword>Bronchopulmonary dysplasia</keyword>
	<keyword>Premature infant</keyword>
</DOC>